Advanced Soft Tissue Sarcoma with Mark Agulnik, MD Case 2

The FDA has granted an orphan drug designation to tigilanol tiglate for the treatment of soft tissue sarcoma.

In season 4, episode 5 of Targeted Talks, Alice P. Chen, MD, discusses important studies that are investigating treatment options for alveolar soft part sarcoma.

In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.

In season 3, episode 2 of Targeted Talks, Mark Agulnik, MD, discusses molecular testing for patients with sarcoma, treatment with targeted therapies, and ongoing research.

INT230-6 is an investigational product candidate made up of cisplatin, vinblastine, and a penetration enhancer molecule being evaluated for patients with soft tissue sarcoma.

Various combination strategies are being explored in soft tissue sarcomas in efforts to increase efficacy.